Heterogeneous Assay of Analytes in Solution Using Polymers

• US 20100035247A1
• Filed: 11/06/2006
• Published: 02/11/2010
• Est. Priority Date: 11/04/2005
• Status: Abandoned Application

• Current Assignee: U.S. Genomics, Inc (Toxic Reports LLC)
• Original Assignee: U.S. Genomics, Inc (Toxic Reports LLC)
• Inventors: Burton, Randall E.
• Application Number:
  US12/084,542
• Publication Number:
  US 20100035247A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6816 characterised by the detection means C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 2537/125 Sandwich assay format
• CPC Class Codes: C12Q 2563/179 the label being a nucleic acid
• CPC Class Codes: G01N 33/5438 Electrodes

Abstract

The invention relates to methods and systems for identifying, quantitating and/or analyzing analytes from samples. The analytes may be organic or inorganic in nature and include but are not limited to pathogens such as viruses.

Claims

1. A method for detecting an analyte in a sample comprising

contacting a sample with a primary binding partner that is bound to a solid support thereby allowing an analyte present in the sample to bind to the primary binding partner,

contacting the bound analyte with a secondary analyte-specific binding partner that is conjugated to a polymer, and

analyzing the polymer bound to the analyte,

wherein the polymer indicates presence of the analyte.

2. The method of claim 1, wherein analyzing the polymer bound to the analyte comprises determining a labeling pattern of the polymer, wherein the labeling pattern of the polymer indicates the identity of the analyte.

3. The method of claim 1, wherein the analyte is a plurality of analytes, the primary binding partner is a plurality of primary binding partners, and the secondary analyte-specific binding partner is a plurality of secondary analyte-specific binding partners.

4. The method of claim 1, wherein the primary binding partner is a primary analyte-specific binding partner.

5. The method of claim 1, wherein the polymer is a nucleic acid.

6. The method of claim 1, wherein the primary binding partner is an antibody or an antigen-binding antibody fragment.

7. The method of claim 1, wherein the secondary analyte-specific binding partner is an antibody or an antigen-binding antibody fragment.

8. The method of claim 1, wherein the secondary analyte-specific binding partner is conjugated to a detectable label.

9. The method of claim 1, wherein the primary binding partner and the secondary analyte-specific binding partner is each labeled with a member of a FRET pair.

10. The method of claim 2, wherein the labeling pattern of the polymer is a binding pattern of one or more sequence-specific probes to the polymer.

11. The method of claim 10, wherein the one or more sequence-specific probes are conjugated to detectable labels.

12. The method of claim 2, wherein the labeling pattern of the polymer is a pattern of detectable labels incorporated into the polymer.

13. The method of claim 2, wherein the labeling pattern of the polymer is a binding pattern of one or more restriction endonucleases to the polymer.

14. The method of claim 1, further comprising analyzing the analyte bound to the secondary analyte-specific binding partner.

15. The method of claim 1, wherein the analyte is a nucleic acid, a carbohydrate, a protein, a peptide, a lipid, a toxin, a cell, a spore, a cellular fragment or a spore fragment.

16. The method of claim 1, wherein the polymer is elongated prior to or simultaneously with its analysis.

17. The method of claim 2, wherein the labeling pattern of the polymer is determined using a focused flow through an electric field.

18. A composition comprising

a nucleic acid bound to an antibody or an antigen-binding antibody fragment and having a unique label,

wherein the unique label is comprised of one or more incorporated detectable labels, one or more bound detectable sequence-specific nucleic acid probes, or one or more bound detectable proteins.

20. The composition of claim 18, wherein the nucleic acid is DNA.

21. The composition of claim 20, wherein the DNA is synthetic DNA.

22. The composition of claim 18, wherein the nucleic acid is bound to the Fc region of the antibody or antigen-binding antibody fragment.

19. A composition comprising

a nucleic acid bound to an antibody or an antigen-binding antibody fragment,

wherein the nucleic acid is 10-1000 kilobases in length.